Abstract
BACKGROUND Inhaled budesonide has shown efficacy for treating COVID-19 in the community but has not yet been tested in effectiveness trials.
METHODS We performed a multicenter, open-label, multi-arm, adaptive platform randomized controlled trial involving people aged ≥65 years, or ≥50 years with comorbidities, and unwell ≤14 days with suspected COVID-19 in the community (PRINCIPLE). Participants were randomized to usual care, usual care plus inhaled budesonide (800µg twice daily for 14 days), or usual care plus other interventions. The co-primary endpoints are time to first self-reported recovery, and hospitalization/death related to COVID-19, both measured over 28 days from randomisation and analysed using Bayesian models.
RESULTS The trial opened on April 2, 2020. Randomization to inhaled budesonide began on November 27, 2020 and was stopped on March 31, 2021 based on an interim analysis using data from March 4, 2021. Here, we report updated interim analysis data from March 25, 2021, at which point the trial had randomized 4663 participants with suspected COVID-19. Of these, 2617 (56.1%) tested SARS-CoV-2 positive and contributed data to this interim budesonide primary analysis; 751 budesonide, 1028 usual care and 643 to other interventions. Time to first self-reported recovery was shorter in the budesonide group compared to usual care (hazard ratio 1.208 [95% BCI 1.076 – 1.356], probability of superiority 0.999, estimated benefit [95% BCI] of 3.011 [1.134 – 5.41] days). Among those in the interim budesonide primary analysis who had the opportunity to contribute data for 28 days follow up, there were 59/692 (8.5%) COVID-19 related hospitalizations/deaths in the budesonide group vs 100/968 (10.3%) in the usual care group (estimated percentage benefit, 2.1% [95% BCI −0.7% – 4.8%], probability of superiority 0.928).
CONCLUSIONS In this updated interim analysis, inhaled budesonide reduced time to recovery by a median of 3 days in people with COVID-19 with risk factors for adverse outcomes. Once 28 day follow up is complete for all participants randomized to budesonide, final analyses of time to recovery and hospitalization/death will be published. (Funded by the National Institute of Health Research/ United Kingdom Research Innovation [MC_PC_19079]; PRINCIPLE ISRCTN number, ISRCTN86534580.)
Competing Interest Statement
Dr. Bafadhel reports grants from AstraZeneca, personal fees from AstraZeneca, Chiesi, GSK, other from Albus Health, ProAxsis, outside the submitted work. Dr. Andersson reports grants from Prenetics and personal fees from Prenetics, outside the submitted work. Dr. Barnes reports grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, personal fees from Teva, personal fees from Covis, during the conduct of the study. Dr. Russell is supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) and reports grants from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Chiesi UK, personal fees from Glaxo-SmithKline, during the conduct of the study. Dr. Ramakrishnan reports grants and non-financial support from Oxford respiratory NIHR BRC, during the conduct of the study; non-financial support from AstraZeneca, personal fees from Australian Government Research Training Program, outside the submitted work. SdeL is Director of the Oxford-RCGP Research and Surveillance Centre. All other authors have no competing interests to declare
Clinical Trial
ISRCTN86534580
Clinical Protocols
https://www.principletrial.org
Funding Statement
The PRINCIPLE trial is funded by a grant to the University of Oxford from UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research as part of the UK Government's rapid research response fund. The views expressed are those of the authors and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Medicines and Healthcare products Regulatory Agency and the South Central-Berkshire Research Ethics Committee (Ref: 20/SC/0158) approved the trial protocol and all recruitment processes.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Writing committee listed below on behalf of the PRINCIPLE Collaborative Group. PRINCIPLE trial collaborators are listed at the end of the manuscript
ly-mee.yu{at}phc.ox.ac.uk, mona.bafadhel{at}ndm.ox.ac.uk, jienchi.dorward{at}phc.ox.ac.uk, gail.hayward{at}phc.ox.ac.uk, ben{at}berryconsultants.net, oghenekome.gbinigie{at}phc.ox.ac.uk, oliver.vanhecke{at}phc.ox.ac.uk, emma.ogburn{at}phc.ox.ac.uk, philip.evans{at}nihr.ac.uk, nick.thomas3{at}nhs.net, mahendragpatel{at}phc.ox.ac.uk, nick{at}berryconsultants.net, michelle{at}berryconsultants.net, Christina{at}berryconsultants.net, mark{at}berryconsultants.net, victoria.harris{at}phc.ox.ac.uk, simon.delusignan{at}phc.ox.ac.uk, monique.andersson{at}ouh.nhs.uk, p.j.barnes{at}imperial.ac.uk, richard.russell{at}ndm.ox.ac.uk, dan.nicolau{at}qut.edu.au, sanjay.ramakrishnan{at}ndm.ox.ac.uk, richard.hobbs{at}phc.ox.ac.uk, christopher.butler{at}phc.ox.ac.uk
Data Availability
Data can be shared with qualifying researchers who submit a proposal with a valuable research question as assessed by a committee formed from the TMG including senior statistical and clinical representation. A contract should be signed.
